SUPRIYA Supriya Lifescience Q3 FY25 results (Oct–Dec 2024) and concall
Supriya Lifescience delivered a strong Q3 FY25 performance, driven by robust demand and strategic focus on high-margin niche products. The company reported significant growth in revenue, EBITDA, and PAT, alongside improved margins. Key operational milestones included the commissioning of Module E and securing the FSSAI license for the whey protein project, reinforcing its backward integrated model and global expansion strategy.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 166 | 186 |
| EBITDA | 65 | 66 |
| Net profit | 46 | 47 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
